Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 20:44:30·⟳ 抓取 20:45:19 +49s·⚡ 决策 10-15 20:48:08 +2m49s·12.0 天前
Actinium制药宣布将于10月19日EANM大会口头报告ATNM-400首个人体I期早期数据（安全性/生物分布/剂量学，非疗效读出）
这是一条'将在4天后作报告'的会议日程预告，不含任何新临床结果（本次只讲Zr-89 PET安全性/生物分布/剂量学，Ac-225治疗疗效尚在后续）；标的为<1美元、约3,000万美元市值、日均成交额极低且带交易所合规通知的微型盘，近期处于下行通道，真正的二元事件在10月19日，提前入场是无edge的投机，方向也不足以做空。
📄 原文Investing.com↗ 原文
Actinium to present early ATNM-400 prostate cancer trial data
UBS now expects a third Fed rate hike after hot September inflation print NEW YORK - Actinium Pharmaceuticals Inc. (NYS…
不做 Actinium Pharmaceuticals（ATNM.US）
无增量事实的会议日程预告（10月19日才披露I期安全性/生物分布/剂量学，非疗效读出），真正二元催化在4天后；标的为<1美元、约3,060万美元市值、日成交极低且带NYSE American上市标准通知的下行微型盘，此刻多空均无edge；可在10月19日读出临近时凭会议摘要/公司IR原文再评估
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Actinium仅预告10月19日EANM口头报告ATNM-400 I期安全性/剂量学数据，无疗效读出、无新增事实；微型盘低流动性叠加上市合规通知与下行趋势，真正催化在4天后，当前不做。
🔎 新鲜度:最早出现 2026-10-15 · 扩散 low · price-in 风险 low ↗
消息传播链
- 预告10月19日EANM口头报告ATNM-400 I期安全性/生物分布/剂量学数据；未检索到公司当日独立IR原文链接，首发应为公司PRNewswire新闻稿，本条为转述市场反应:美股盘前价0.95美元、-2.5%，成交仅1,106股，无显著反应
关键理由
- 本条新闻的实质信息增量为零：数据本身要到10月19日才披露，且披露内容为影像/剂量学而非抗肿瘤疗效，无法在当下形成可证伪的多头假设
- ATNM为约3,060万美元市值、股价约0.95美元的临床期微型盘，20日累计-21%、处于52周低位附近，2026年5月已收到NYSE American上市标准通知，提前博弈的流动性与退市风险高
主要风险
- 若10月19日剂量学/肿瘤摄取数据显著超预期，微型盘可能出现高波动短线跳升，但这属于读出日当天事件，不构成本次预告消息的入场理由
- 新闻为AI生成且标题与正文（UBS加息）错配，信息载体质量差，需以公司IR/会议摘要原文为准
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-15 · 影响 weakens
未发现已披露的人体疗效数据、授权合作或合规恢复等可支撑当下做多的增量利好；近期股价20日-21%且处下行通道
检索:Actinium ATNM-400 human efficacy data readout / partnership / NYSE American compliance 2026 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-15 · 影响 none
本条消息本身非利空，亦无当日新增融资/暴雷事实，仅凭低价与旧合规通知不满足做空的强催化要求
检索:Actinium Pharmaceuticals ATNM negative news dilution October 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失未改变方向，仅强化'不在预告阶段提前入场'的结论
方向:无可用于校准的对齐先例；本次为AVOID，结论建立在无信息增量与标的结构风险上，不依赖先例涨幅
涨幅量级:未用先例校准幅度：真正可交易的事件是10月19日实际读出，应在临近该日并取得会议摘要/公司IR原文后再单独评估
形态:微观盘临床期biotech对'会议日程预告'通常无显著重定价，真正波动集中在数据披露当日；本条盘前无量无反应与该模式一致
工具执行结果 · 成功 6 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 15 ms
{"result": "search_processed_events:agent query=`actinium pharmaceuticals atnm-400 prostate cancer eanm phase 1 data presentation | actinium pharmaceuticals first-in-human atnm-400 dosimetry pet abstract | atnm-400 actinium-225 r`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 1,510 ms
{ - web_search 成功 doubao_search · 2,596 ms
豆包搜索结果（原始查询:Actinium Pharmaceuticals ATNM-400 EANM 2026 presentation prostate cancer Phase 1；API SearchType:web） - web_search 成功 doubao_search · 2,361 ms
豆包搜索结果（原始查询:Actinium Pharmaceuticals ATNM NYSE American listing standards notice 2026 delisting price；API SearchType:web） - web_search 成功 doubao_search · 2,099 ms
豆包搜索结果（原始查询:"Actinium" ATNM-400 EANM October 19 2026 press release first-in-human data presented；API SearchType:web）
原文全文
展开原文 · 1,921 字
UBS now expects a third Fed rate hike after hot September inflation print
NEW YORK - Actinium Pharmaceuticals Inc. (NYSE American:ATNM) announced that early results from its first-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant prostate cancer will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine on October 19 in Vienna, Austria.
The presentation will cover the ongoing Phase 1 dose-escalation study of ATNM-400, an Actinium-225 antibody radioconjugate targeting a non-PSMA antigen. The study evaluates the safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400 using serial PET imaging to assess tumor uptake, distribution, and clearance. The dosimetry estimates will inform therapeutic Actinium-225-labeled ATNM-400 dosing, according to a press release statement.
ATNM-400 is being developed for patients with metastatic castration-resistant prostate cancer, including those with PSMA-low or PSMA-negative disease and patients who do not respond to or progress after PSMA-directed therapies.
"These first clinical data from ATNM-400 mark an important milestone for Actinium and for prostate cancer treatment beyond PSMA," said Sandesh Seth, the company’s Chairman and CEO.
The oral presentation is scheduled for Monday, October 19, 2026, from 4:45 to 6:15 p.m. CEST in Hall G1 at the conference venue. The abstract is numbered OP-525 and is part of the Theranostics Track: Prostate Cancer Therapy II session.
Actinium Pharmaceuticals develops targeted radiotherapies for cancer treatment. The company’s pipeline includes solid tumor therapeutics, treatments for acute myeloid leukemia and myelodysplastic syndrome in collaboration with the National Cancer Institute, and targeted conditioning agents for bone marrow transplant.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - Actinium Pharmaceuticals Inc. (NYSE American:ATNM) announced that early results from its first-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant prostate cancer will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine on October 19 in Vienna, Austria.
The presentation will cover the ongoing Phase 1 dose-escalation study of ATNM-400, an Actinium-225 antibody radioconjugate targeting a non-PSMA antigen. The study evaluates the safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400 using serial PET imaging to assess tumor uptake, distribution, and clearance. The dosimetry estimates will inform therapeutic Actinium-225-labeled ATNM-400 dosing, according to a press release statement.
ATNM-400 is being developed for patients with metastatic castration-resistant prostate cancer, including those with PSMA-low or PSMA-negative disease and patients who do not respond to or progress after PSMA-directed therapies.
"These first clinical data from ATNM-400 mark an important milestone for Actinium and for prostate cancer treatment beyond PSMA," said Sandesh Seth, the company’s Chairman and CEO.
The oral presentation is scheduled for Monday, October 19, 2026, from 4:45 to 6:15 p.m. CEST in Hall G1 at the conference venue. The abstract is numbered OP-525 and is part of the Theranostics Track: Prostate Cancer Therapy II session.
Actinium Pharmaceuticals develops targeted radiotherapies for cancer treatment. The company’s pipeline includes solid tumor therapeutics, treatments for acute myeloid leukemia and myelodysplastic syndrome in collaboration with the National Cancer Institute, and targeted conditioning agents for bone marrow transplant.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
18689fe836· 2026-10-15 20:48 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前